中国组织工程研究与临床康复
中國組織工程研究與臨床康複
중국조직공정연구여림상강복
JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH
2010年
12期
2249-2252
,共4页
血浆置换%重型肝炎%膜型血浆分离器%人工肝%生物膜材料
血漿置換%重型肝炎%膜型血漿分離器%人工肝%生物膜材料
혈장치환%중형간염%막형혈장분리기%인공간%생물막재료
背景:人工肝血浆置换目前普遍应用于临床,给重型肝炎患者的治疗提供了新的手段.但是不同材料制备的膜型血浆分离器由于膜面积和孔径等存在差异,治疗效果也不尽相同.目的:观察由乙烯、乙烯醇共聚物制备的新型膜型血浆分离器Evacure-4A(EC-4A)治疗重型肝炎的临床疗效,并与由聚乙烯磺基制备的PS-06膜型血浆分离器进行对比分析.方法:65例重型肝炎患者在常规治疗基础上加用血浆置换治疗,其中治疗组35例应用新型膜型血浆分离器EC-4A,对照组30例应用PS-06膜型血浆分离器.检测治疗前后肝功能、肾功能、血电解质及血氨指标.结果与结论:PS-06对照组和Evacure-4A治疗组患者经血浆置换治疗后肝肾功能各指标均有明显好转,其中治疗组在治疗后的总胆红素、谷丙转氨酶、凝血酶原时间的改善程度和血清白蛋白的上升幅度以及血氨清除水平高于对照组(P<0.05),差异有显著性意义.结果提示Evacure-4A膜型血浆分离器治疗重型肝炎更安全有效.
揹景:人工肝血漿置換目前普遍應用于臨床,給重型肝炎患者的治療提供瞭新的手段.但是不同材料製備的膜型血漿分離器由于膜麵積和孔徑等存在差異,治療效果也不儘相同.目的:觀察由乙烯、乙烯醇共聚物製備的新型膜型血漿分離器Evacure-4A(EC-4A)治療重型肝炎的臨床療效,併與由聚乙烯磺基製備的PS-06膜型血漿分離器進行對比分析.方法:65例重型肝炎患者在常規治療基礎上加用血漿置換治療,其中治療組35例應用新型膜型血漿分離器EC-4A,對照組30例應用PS-06膜型血漿分離器.檢測治療前後肝功能、腎功能、血電解質及血氨指標.結果與結論:PS-06對照組和Evacure-4A治療組患者經血漿置換治療後肝腎功能各指標均有明顯好轉,其中治療組在治療後的總膽紅素、穀丙轉氨酶、凝血酶原時間的改善程度和血清白蛋白的上升幅度以及血氨清除水平高于對照組(P<0.05),差異有顯著性意義.結果提示Evacure-4A膜型血漿分離器治療重型肝炎更安全有效.
배경:인공간혈장치환목전보편응용우림상,급중형간염환자적치료제공료신적수단.단시불동재료제비적막형혈장분리기유우막면적화공경등존재차이,치료효과야불진상동.목적:관찰유을희、을희순공취물제비적신형막형혈장분리기Evacure-4A(EC-4A)치료중형간염적림상료효,병여유취을희광기제비적PS-06막형혈장분리기진행대비분석.방법:65례중형간염환자재상규치료기출상가용혈장치환치료,기중치료조35례응용신형막형혈장분리기EC-4A,대조조30례응용PS-06막형혈장분리기.검측치료전후간공능、신공능、혈전해질급혈안지표.결과여결론:PS-06대조조화Evacure-4A치료조환자경혈장치환치료후간신공능각지표균유명현호전,기중치료조재치료후적총담홍소、곡병전안매、응혈매원시간적개선정도화혈청백단백적상승폭도이급혈안청제수평고우대조조(P<0.05),차이유현저성의의.결과제시Evacure-4A막형혈장분리기치료중형간염경안전유효.
BACKGROUND: The artificial liver plasmapheresis provides a novel method for severe hepatitis patients in clinic. However, the discrepancy of membrane plasma separator result in varied therapeutic efficacy. OBJECTIVE: To observe the therapeutic efficacy of the new type of membrane plasma separator Evacure-4A prepared by ethylene vinyl alcohol copolymer on severe hepatitis patients, in addition, to compare the results versus that of PS-06 membrane plasma separator. METHODS: Totally 65 severe hepatitis patients were given similar basic medical treatment and plasma exchange. In the treatment group (n=35), patients were received plasma exchange using Evacure-4A membrane plasma separator, and those in the control group (n=30), were using PS-06 membrane plasma separator. The hepatic function, renal function, blood biochemistry and blood ammonia were tested before and after the treatment. RESULTS AND CONCLUSION: Evacure-4A and PS-06 membrane plasma separators could both efficiently improve the hepatic function and renal function. The improvement of total bilirubin, alanine aminotransferase, prothrombin time, the increasing level of serum albumin and decreasing of blood ammonia in the treatment group were better than the control group (P < 0.05), there was obviously statistical significance. It is available and safe using the Evacure-4A membrane plasma separator to treat severe hepatitis.
